AI Engines For more Details: Perplexity Kagi Labs You
Prebiotic Effects: Levan has been studied for its potential prebiotic properties. As a fermentable fiber, it can serve as a substrate for beneficial bacteria in the gut, promoting their growth and activity. By stimulating the growth of beneficial gut bacteria, levan may help improve gut health and support the balance of the gut microbiota. A healthy gut microbiota is associated with various health benefits, including improved digestion, immune function, and overall well-being.
Blood Sugar Regulation: Some research suggests that certain types of dietary fibers, including levan, may have beneficial effects on blood sugar levels. By slowing down the absorption of glucose from the digestive tract into the bloodstream, fibers like levan can help regulate blood sugar levels and prevent rapid spikes and crashes in blood glucose. This effect may be particularly beneficial for individuals with diabetes or those at risk of developing diabetes.
Digestive Health: Like other dietary fibers, levan can add bulk to stool and promote bowel regularity. By increasing fecal bulk and softening stool, levan may help prevent constipation and promote overall digestive health. Additionally, the fermentation of levan by gut bacteria produces short-chain fatty acids (SCFAs), which provide energy for colon cells and help maintain a healthy gut environment.
Weight Management: Dietary fibers like levan can contribute to feelings of fullness and satiety when consumed as part of a meal or snack. By increasing the bulk of food in the digestive tract and delaying gastric emptying, levan may help reduce hunger and calorie intake, which could support weight management efforts.
Immune Function: While direct evidence is limited, some research suggests that certain dietary fibers, including levan, may have immunomodulatory effects. By influencing the composition and activity of the gut microbiota, dietary fibers can indirectly impact immune function. A healthy gut microbiota is essential for maintaining a balanced immune response and protecting against infections and inflammatory conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Increases |
| species | Escherichia coli | Increases |
| species | Faecalibacterium prausnitzii | Increases |
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
| species | Paenibacillus polymyxa | Increases |
| species | Streptococcus thermophilus | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 1.2 | 1 | 0.2 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | |
| Allergic Rhinitis (Hay Fever) | 2.2 | 1.7 | 0.29 |
| Allergies | 4.1 | 2.5 | 0.64 |
| Allergy to milk products | 0.7 | 1.4 | -1 |
| Alopecia (Hair Loss) | 0.1 | -0.1 | |
| Alzheimer's disease | 3.1 | 3.5 | -0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 1.4 | -1.8 |
| Ankylosing spondylitis | 1.9 | 1.6 | 0.19 |
| Anorexia Nervosa | 2.5 | 0.7 | 2.57 |
| Antiphospholipid syndrome (APS) | 1 | -1 | |
| Asthma | 3.1 | 4 | -0.29 |
| Atherosclerosis | 1.6 | 2.5 | -0.56 |
| Atrial fibrillation | 1.3 | 3 | -1.31 |
| Autism | 4.6 | 4.4 | 0.05 |
| Autoimmune Disease | 1.8 | 0.7 | 1.57 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 1.9 | 0 | 0 |
| Biofilm | 0.5 | 1.4 | -1.8 |
| Bipolar Disorder | 1.1 | 1.8 | -0.64 |
| Brain Trauma | 3.1 | 0.6 | 4.17 |
| Breast Cancer | |||
| Cancer (General) | 0.9 | 0.9 | |
| Carcinoma | 0.6 | 1.3 | -1.17 |
| Celiac Disease | 1.9 | 2.3 | -0.21 |
| Cerebral Palsy | 1.2 | 1.2 | 0 |
| Chronic Fatigue Syndrome | 2.9 | 2.2 | 0.32 |
| Chronic Kidney Disease | 1.8 | 0.8 | 1.25 |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 2.7 | -2.38 |
| Chronic Urticaria (Hives) | 1.3 | 0.6 | 1.17 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 0.9 | 0.33 |
| Cognitive Function | 2 | 2.2 | -0.1 |
| Colorectal Cancer | 3.1 | 4.5 | -0.45 |
| Constipation | 1.1 | 1.2 | -0.09 |
| Coronary artery disease | 3 | 0.6 | 4 |
| COVID-19 | 5.7 | 4.5 | 0.27 |
| Crohn's Disease | 4.3 | 3.8 | 0.13 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | 0 | 0 |
| cystic fibrosis | 1.4 | 0 | 0 |
| d-lactic acidosis (one form of brain fog) | 1.2 | -1.2 | |
| deep vein thrombosis | 2.3 | 0.3 | 6.67 |
| Denture Wearers Oral Shifts | 0.6 | 1.5 | -1.5 |
| Depression | 5.2 | 6.5 | -0.25 |
| Dermatomyositis | 0.6 | -0.6 | |
| Eczema | 1.9 | 2.4 | -0.26 |
| Endometriosis | 1.7 | 3 | -0.76 |
| Eosinophilic Esophagitis | 0.6 | 0.6 | |
| Epilepsy | 2.3 | 2.8 | -0.22 |
| erectile dysfunction | 0.7 | 0.7 | 0 |
| Fibromyalgia | 2.5 | 0.6 | 3.17 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 2.9 | -0.16 |
| gallstone disease (gsd) | 1.7 | 1 | 0.7 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1 | -0.25 |
| Generalized anxiety disorder | 2.6 | 1.5 | 0.73 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 1.4 | 1.4 | |
| Gout | 2.5 | -2.5 | |
| Graves' disease | 2.6 | 1.5 | 0.73 |
| Gulf War Syndrome | 0.4 | 0.9 | -1.25 |
| Halitosis | 0.6 | 1.2 | -1 |
| Hashimoto's thyroiditis | 2.5 | 0.8 | 2.13 |
| Heart Failure | 2.2 | 2.6 | -0.18 |
| Hidradenitis Suppurativa | 0.5 | 1.3 | -1.6 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 2.2 | 1.6 | 0.38 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.6 | 1.33 |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 4.3 | 2.5 | 0.72 |
| Hypothyroidism | 1.3 | 0.2 | 5.5 |
| Hypoxia | 1.1 | 1.5 | -0.36 |
| IgA nephropathy (IgAN) | 1.5 | 1.3 | 0.15 |
| Inflammatory Bowel Disease | 5.9 | 3.7 | 0.59 |
| Insomnia | 2.7 | 3 | -0.11 |
| Intelligence | 0.5 | 1.3 | -1.6 |
| Intracranial aneurysms | 1.2 | 1.1 | 0.09 |
| Irritable Bowel Syndrome | 4.4 | 3.5 | 0.26 |
| ischemic stroke | 1.8 | 2.6 | -0.44 |
| Liver Cirrhosis | 2.6 | 3 | -0.15 |
| Long COVID | 4.4 | 3.2 | 0.38 |
| Low bone mineral density | 0.2 | 0.2 | |
| Lung Cancer | 1.3 | 0.1 | 12 |
| Lymphoma | 0.5 | 0 | 0 |
| Mast Cell Issues / mastitis | 0.8 | 0.6 | 0.33 |
| ME/CFS with IBS | 1.7 | 0.6 | 1.83 |
| ME/CFS without IBS | 0.6 | 0.6 | 0 |
| membranous nephropathy | 0.6 | -0.6 | |
| Menopause | 1.3 | 0.8 | 0.63 |
| Metabolic Syndrome | 4.4 | 3 | 0.47 |
| Mood Disorders | 4.7 | 6.9 | -0.47 |
| multiple chemical sensitivity [MCS] | 0.6 | 1.9 | -2.17 |
| Multiple Sclerosis | 4.1 | 2.5 | 0.64 |
| Multiple system atrophy (MSA) | 0.9 | -0.9 | |
| myasthenia gravis | 1.1 | 1.3 | -0.18 |
| neuropathic pain | 1.1 | 1.1 | |
| Neuropathy (all types) | 0.6 | 1.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.9 | -0.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 3.5 | 0.17 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.8 | 1.25 |
| Obesity | 6.7 | 4.1 | 0.63 |
| obsessive-compulsive disorder | 2.4 | 2.5 | -0.04 |
| Osteoarthritis | 2.3 | 1.5 | 0.53 |
| Osteoporosis | 3.5 | 1.9 | 0.84 |
| pancreatic cancer | 0.6 | 0.9 | -0.5 |
| Parkinson's Disease | 5.6 | 4.2 | 0.33 |
| Peanut Allergy | 0.6 | -0.6 | |
| Polycystic ovary syndrome | 4 | 3 | 0.33 |
| Postural orthostatic tachycardia syndrome | |||
| primary biliary cholangitis | 1.6 | 1.8 | -0.13 |
| Primary sclerosing cholangitis | 1.6 | 2.1 | -0.31 |
| Psoriasis | 0.6 | 2.3 | -2.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 4 | 0.3 |
| Rosacea | 1.1 | 1.1 | |
| Schizophrenia | 2 | 3.2 | -0.6 |
| scoliosis | 0.5 | 0.2 | 1.5 |
| sensorineural hearing loss | 0.5 | 0.2 | 1.5 |
| Sjögren syndrome | 2.4 | 2 | 0.2 |
| Sleep Apnea | 1.7 | 0.5 | 2.4 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 2 | -3 |
| Stress / posttraumatic stress disorder | 2.3 | 1.2 | 0.92 |
| Systemic Lupus Erythematosus | 1.9 | 2.3 | -0.21 |
| Tic Disorder | 0 | 1.4 | 0 |
| Tourette syndrome | 1.4 | 0.6 | 1.33 |
| Type 1 Diabetes | 3.4 | 2.9 | 0.17 |
| Type 2 Diabetes | 4.3 | 3 | 0.43 |
| Ulcerative colitis | 4.9 | 4.4 | 0.11 |
| Unhealthy Ageing | 1.3 | 2 | -0.54 |
| Vitiligo | 0.6 | 1.4 | -1.33 |
